Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 14, 2016 10:52 ET | Source: Neovacs, Inc.

NEOVACS Obtains South Korea Health Authority Approval for IND Application With IFNa Kinoid in Lupus

PARIS, April 14, 2016 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that South Korea health...
January 29, 2016 02:15 ET | Source: Neovacs, Inc.

2016 Financial Calendar

PARIS, Jan. 29, 2016 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today its financial reporting...
January 06, 2016 02:15 ET | Source: Neovacs, Inc.

Neovacs Secures €5 Million, From the Public Funding Program «Investments for the Future» to Support Clinical and Industrial Development for the Therapeutic Vaccine INFa Kinoïd

PARIS and BOSTON, Jan. 06, 2016 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), has concluded an agreement which provides non-dilutive funding of five million euros for over the next four...
December 15, 2015 02:15 ET | Source: Neovacs, Inc.

Neovacs Signs a Strategic Partnering Agreement With the Korean Company CKD Pharmaceutical Corp.

PARIS and BOSTON, Dec. 15, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), today announced the signature of an exclusive licensing agreement with Chong Kun Dang (CKD) Pharmaceutical Corp....
October 02, 2015 02:15 ET | Source: Neovacs, Inc.

Neovacs Reports First-Half 2015 Financial Results

PARIS and BOSTON, Oct. 2, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced its results for the six...
September 24, 2015 02:15 ET | Source: Neovacs, Inc.

NEOVACS Initiates Phase IIb Trial of IFNa-Kinoid for the Treatment of Lupus

PARIS and BOSTON, Sept. 24, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today it has begun...
September 09, 2015 02:15 ET | Source: Neovacs, Inc.

Neovacs Confirms Potent and Long-Lasting Biological Activity of IFNa-Kinoid 4 Years After Patient Dosing in Phase I/IIa Trial

Company Presented Extended Follow-Up Data on IFNα-Kinoid at 11th International Congress on Lupus PARIS and BOSTON, Sept. 9, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), a leader...
September 01, 2015 02:15 ET | Source: Neovacs, Inc.

Neovacs Receives First Regulatory Approvals for a Phase IIb Trial of IFNa-Kinoid in Lupus

PARIS and BOSTON, Sept. 1, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that it has been...
April 14, 2015 02:15 ET | Source: Neovacs, Inc.

Neovacs to Present at ChinaBio Partnering Forum

PARIS and BOSTON, April 14, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today that is has been...
March 23, 2015 03:15 ET | Source: Neovacs, Inc.

Neovacs Strengthens North American Presence With Formation of U.S. Subsidiary

PARIS, March 23, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV, FR0004032746), a leader in active immunotherapies for the treatment of autoimmune diseases, is proud to announce the...